Search
News & Events
Respiratory research program recruits 400th participant, marking key milestoneIn September 2024, the Western Australian Epithelial Research Program (WAERP) reached a significant milestone by recruiting its 400th participant.
News & Events
Kids Easy Breathing Study KickstartsThe Kids Easy Breathing Study kickstarts this month, with the aim of finding out how the airway surface is different between infants who develop chronic lung disease after contracting bronchiolitis compared with those who don’t.
News & Events
Study shows climate change will devastate children’s health without fast global actionIncreased numbers of preterm births, higher incidence of respiratory disease and death, and more children in hospitals are some of the stark health outcomes the world is facing from the impacts of extreme climate change.
News & Events
Unique twin study reveals clues to childhood allergiesA study published in Science Advances has revealed that while genetics play a significant role in shaping children's immune systems, environmental factors also influence key immune responses, offering opportunity for preventing allergic diseases.
Our team uses AI to quickly analyse large amounts of genetic data to help discover alternate medications and improve existing treatments.
Research
Erdosteine in children and adults with bronchiectasis (BETTER trial): study protocol for a multicentre, double-blind, randomised controlled trialBronchiectasis is a worldwide chronic lung disorder where exacerbations are common. It affects people of all ages, but especially Indigenous populations in high-income nations. Despite being a major contributor to chronic lung disease, there are no licensed therapies for bronchiectasis and there remain relatively few randomised controlled trials (RCTs) conducted in children and adults.
Research
Thoracic Society of Australia and New Zealand (TSANZ) position statement on chronic suppurative lung disease and bronchiectasis in children, adolescents and adults in Australia and New ZealandThis position statement, updated from the 2015 guidelines for managing Australian and New Zealand children/adolescents and adults with chronic suppurative lung disease (CSLD) and bronchiectasis, resulted from systematic literature searches by a multi-disciplinary team that included consumers.
Research
Novel intranasal phage-CaEDTA-ceftazidime/avibactam triple combination therapy demonstrates remarkable efficacy in treating Pseudomonas aeruginosa lung infectionGiven the rise of multidrug-resistant (MDR) Pseudomonas aeruginosa infections, alternative treatments are needed. Anti-pseudomonal phage therapy shows promise, but its clinical application is limited due to the development of resistance and a lack of biofilm penetration.
Research
Ancestral SARS-CoV-2, but not Omicron, replicates less efficiently in primary pediatric nasal epithelial cellsChildren typically experience more mild symptoms of Coronavirus Disease 2019 (COVID-19) when compared to adults. There is a strong body of evidence that children are also less susceptible to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection with the ancestral viral isolate.
Research
Evaluation of the implementation and clinical effects of an intervention to improve medical follow-up and health outcomes for Aboriginal children hospitalised with chest infectionsAboriginal children hospitalised with acute lower respiratory infections (ALRIs) are at-risk of developing bronchiectasis, which can progress from untreated protracted bacterial bronchitis, often evidenced by a chronic (>4 weeks) wet cough following discharge. We aimed to facilitate follow-up for Aboriginal children hospitalised with ALRIs to provide optimal management and improve their respiratory health outcomes.